



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Alberto Pappo, M.D.

Committee: Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Meeting Date: June 22, 2017

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: At the advisory committee meeting, information will be presented to gauge investigator interest in exploring potential pediatric development plans for two products, Olaratumab and Prexasertib, in various stages of development for adult cancer indications, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Employer's Contracts/grants	Sponsor, Eli Lilly	\$50,001 – 100,000;

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of this interest, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature

\_\_\_\_\_/6/1/17\_\_\_\_\_  
Date